Anifrolumab
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Anifrolumab
Anifrolumab: Known uses and market status in Australia
Summary
The TxGNN model produced no candidate with a score of 0.99 or higher for Anifrolumab, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| systemic lupus erythematosus | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 14189T | Saphnelo | Solution concentrate for I.V. infusion 3 | Valid |
Safety Considerations
- Drug Interactions: The interaction query completed with one pharmacology entry. It identifies the drug’s target (IFNAR1) rather than a clinical drug-drug interaction.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.